Paraoxonase

PreclinicalProtein / enzyme

UUS Department of Veterans Affairs

Paraoxonase is one of 7 small molecule programs targeting Carotid Artery Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Carotid Artery DiseaseActive, not recruiting

Carotid Artery DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Carotid Artery Disease

#DrugCompanyPhaseTrials

Lithobid

SSolvay Pharmaceuticals

Optison

1 3

Bayer Aspirin

Plavix

Zocor

DPA-714

UUniversity of Alabama at Birmingham

Phase 1

1 7

Paraoxonase

UUS Department of Veterans Affairs

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Carotid Artery Disease1 trial

Paraoxonase and LDL Oxidation in Carotid Artery Disease

Completed·UUS Department of Veterans Affairs··NCT00011258·1,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Paraoxonase. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Paraoxonase compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Paraoxonase. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — US Department of Veterans Affairs company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Preclinical[1]
Company: UUS Department of Veterans Affairs

Paraoxonase

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Carotid Artery Disease1 trial

References

Drug Info

Quick Facts

Related News